News / Events
HORIZON 2020 – Patient Questionnaire
Myeloma Patients Europe (MPE) is running a survey for European myeloma patients to understand their quality of life and how this is impacted by treatment side-effects. To gain knowledge about the current Multiple Myeloma (MM) disease situation in Europe, we ask...
Summary of the first project year
The Multiple Myeloma horizon 2020 (MMh2020) initiative was started on November 1st 2016 and included the following consortium partners: SkylineDx B.V., the Department of Haematology of the Erasmus University Medical Center Rotterdam (Erasmus MC), the Department of...
Project team meeting in Rotterdam
At our third HORIZON 2020 project team meeting we welcomed all consortium partners at the SkylineDx headquarters in Rotterdam. During this successful assembly, a detailed overview of the currently included study cohort was given and the MPE presented their developed...
One-year anniversary!
Today we celebrate the one-year anniversary of our the Multiple Myeloma Horizon 2020 research project. Within this first period we have made considerable progress towards our central goal of developing a personalized medicine tool that is capable of predicting the...
HORIZON 2020 project team meeting
During the recent 22nd EHA congress in Madrid we have had the opportunity to host a successful HORIZON 2020 project team meeting. During this in-person gathering of all consortium partners, different representatives presented their work and elaborated on the progress...
New milestone in the Horizon2020 project
We are happy to announce a new milestone in the Horizon2020 project: the first patient samples have arrived and are measured at the SkylineDx lab.
New MM treatment gains funding
5 October 2016 New MM treatment gains funding SkylineDx has received Horizon 2020 funding to develop a gene-expression profiling technology intended to predict treatment strategies for patients with multiple myeloma (MM). The announcement comes as SkylineDx prepares...
